Pharmaceutical

Sen. Elizabeth Warren probes abortion access amid state...

Sen. Elizabeth Warren (D-Mass.) is launching a fresh round of questioning on sta...

STAT+: Pharmalittle: Pfizer touts study data for hemoph...

A report by nonpartisan congressional researchers suggests there are at least so...

STAT+: European regulatory panel weighing against appro...

A European regulatory panel has taken a negative view of whether an ALS treatmen...

Opinion: More hospitals are offering child care. But th...

“Basically no one leaves that utilizes the child care center."

STAT+: Lured by a bigger payday, a medical device maker...

Lured by a bigger payday from insurance, a medical device maker sold fake plasti...

STAT wants to know your pick for a great summer read or...

We want to hear from you! We're gathering recommendations for books and podcasts...

Opinion: In defense of being ‘Cali sober’

Hardcore proponents of abstinence-based recovery, such as Alcoholics Anonymous, ...

STAT+: Just how vulnerable is Medicare drug negotiation...

A new report suggests there are at least some parts of the law setting up Medica...

Valneva seeks Health Canada approval for chikungunya va...

The single-shot vaccine is intended for persons aged 18 years and above.

Roche Canada and pCPA conclude talks for Vabysmo eye th...

Vabysmo helps treat neovascular (wet) age-related macular degeneration (AMD) and...

Sun Pharma and Philogen sign licence agreement for anti...

Sun Pharma will commercialise Nidlegy in three countries to treat skin cancers.

Early signals suggest oral SERD’s potential for more br...

The company is presenting exploratory results at ASCO, which demonstrates new us...

US companies drive 2023 drug launches positioned for bl...

Notably, American pharmaceutical mega-cap companies take the lead, with 80% repr...

AION Labs and BioMed X launch sixth challenge for AI-dr...

The startup will utilise cutting edge methods to accelerate drug discovery resea...

Catalent CEO drops FY2023 revenue forecast by $450m aft...

In an investor call on 19 May, Catalent reduced its annual net revenue forecast ...

Abiogen acquires EffRx to fortify bone disease portfolio

The Italian pharmaceutical company Abiogen Pharma acquired Effrx Pharmaceuticals...